biostudies-literatureOriol-Tordera BNIAID NIH HHSMedical Research Council103956https://www.ebi.ac.uk/biostudies/studies/S-EPMC8938861biostudies-literatureUnknown78<h4>Background</h4>The BCN02-trial combined therapeutic vaccination with a viral latency reversing agent (romidepsin, RMD) in HIV-1-infected individuals and included a monitored antiretroviral pause (MAP) as an efficacy read-out identifying individuals with an early or late (< or > 4weeks) viral-rebound. Integrated -omics analyses were applied prior treatment interruption to identify markers of virus control during MAP.<h4>Methods</h4>PBMC, whole-genome DNA methylation and transcriptomics were assessed in 14 BCN02 participants, including 8 Early and 4 Late viral-rebound individuals. Chromatin state, histone marks and integration analysis (histone-3 acetylation (H3Ac), viral load, proviral levels and HIV-specific T cells responses) were included. REDUC-trial samples (n = 5) were included asEBioMedicineEpigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome.PMC8938861MR/N023668/1P01 AI131568Hanke TParedes RSanchez-Pla ATolstrup MEsteller MLlano ABerdasco MGoncalves EDuran-Castells CCatala-Moll FCedeno SMolto JMartinez-Picado JCombadiere BEsteve-Codina ASogaard OSMothe BCalle MLRuiz-Riol MRosas-Umbert MClotet BOriol-Tordera BPuertas MCHartigan-O'Connor DBrander CMeulbroek MfalseEpigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome.<h4>Background</h4>The BCN02-trial combined therapeutic vaccination with a viral latency reversing agent (romidepsin, RMD) in HIV-1-infected individuals and included a monitored antiretroviral pause (MAP) as an efficacy read-out identifying individuals with an early or late (< or > 4weeks) viral-rebound. Integrated -omics analyses were applied prior treatment interruption to identify markers of virus control during MAP.<h4>Methods</h4>PBMC, whole-genome DNA methylation and transcriptomics were assessed in 14 BCN02 participants, including 8 Early and 4 Late viral-rebound individuals. Chromatin state, histone marks and integration analysis (histone-3 acetylation (H3Ac), viral load, proviral levels and HIV-specific T cells responses) were included. REDUC-trial samples (n = 5) were included as2022-01-01T00:00:00Z2022 Apr2026-06-01T02:09:42.73Z2025-04-05T09:49:34.267ZS-EPMC89388613532578010.1016/j.ebiom.2022.103956